Cellectis shares drop after Allogene arbitration win over CAR-T therapy dispute, with Allogene gaining full development and commercial control in US, EU, UK, while clearing path for global rights from Servier.
Cellectis S.A. (NASDAQ: CLLS) saw a significant drop in their shares following an arbitration outcome favoring Allogene Therapeutics Inc. (NASDAQ: ALLO) over a dispute related to the CAR-T therapy, cemacabtagene ansegedleucel (cema-cel). This win solidified Allogene's control over the development and commercialization of cema-cel in the U.S., the EU, and the U.K., while paving the way for full global commercialization rights from Servier. The news impacted Cellectis stock on Tuesday.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments